Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema
Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults with mild to severe eczema
Potent probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults with mild to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐4 weeks) · children and adults, most with moderate to severe eczema
Potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with moderate‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time point within 1‐2 weeks) · adults with eczema
Very potent showed no clear difference in clinician‐reported signs of eczema: IGA (number with cleared or… compared with potent topical corticosteroid (low certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema: PGA (number judging excellent); short term (day 8) · adults with eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · adults with eczema
It is very uncertain whether very potent changes local adverse events: skin thinning; end of treatment (day 11‐day 22) compared with potent topical corticosteroid (very low certainty).
1 finding from 1 review
Systemic adverse events: abnormal cortisol · adults with eczema
1 finding from 1 review
Congenital abnormality · pregnant women
Potent/very potent topical corticosteroids may leads to lower congenital abnormality compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 0.56
9342 participants
Low
Orofacial cleft · pregnant women
Potent/very potent topical corticosteroids may leads to higher orofacial cleft compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.5
36348 participants
Low
Low birthweight · pregnant women
Potent/very potent topical corticosteroids may leads to higher low birth weight compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.58
47651 participants
Low
Preterm birth · pregnant women
Potent/very potent topical corticosteroids may leads to higher preterm delivery compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.05
47651 participants
Low
Foetal death · pregnant women
Potent/very potent topical corticosteroids may leads to higher foetal death compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.14
37086 participants
Low
Low Apgar score · pregnant women
Potent/very potent topical corticosteroids may leads to higher low Apgar score compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.03
7514 participants
Low